HUTCHMED announced positive Phase II trial results for fanregratinib in treating advanced intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement. The study showed a 42.5% objective response rate and median overall survival of 16.6 months in patients previously treated with chemotherapy and immunotherapy. The drug demonstrated rapid, durable disease control and a manageable safety profile. Based on these results, China’s NMPA has granted priority review for fanregratinib’s approval, potentially offering a new targeted treatment option for this difficult-to-treat cancer.
Western Union and Intermex announced that regulatory approvals for Western Union's acquisition of Intermex have been received from 51 U.S. states and international jurisdictions, with only one U.S. state, New York, pending approval. Both companies ar...
Modern Therapy Group has introduced a virtual intensive outpatient program (IOP) designed for adults dealing with depression, anxiety, trauma, and other mental health issues. This program offers structured, clinician-led treatment five days a week vi...
Meyer Wilson Werning, an investor protection law firm, is investigating UBS advisor Daniel Merithew Allen for allegedly recommending unapproved investments in 99 Acquisition Group LLC to clients. This practice, known as "selling away," violates FINRA...
NEWMEDIA.COM highlights a major shift in digital marketing where AI Visibility Infrastructure integrates search, authority, content, and analytics to ensure brands are discoverable and recommended by AI systems. Traditional search rankings are becomi...
An insider at Oruka Therapeutics sold 105,000 shares valued at $6.2 million. Such a large sale by someone within the company could indicate changes in confidence or strategy. Investors should watch for further developments or official statements from...
